Advanced Solid Tumor Clinical Trials in Columbus, Ohio

10 studies are recruiting for advanced solid tumor in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

   This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   James Cancer Hospital and Solove Research Institute, Columbus, Ohio

   Locations

   37 in total

   Run by

   BeOne Medicines

   See if you can join NCT06233942 on ClinicalTrials.gov

2. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   James Cancer Hospital and Solove Research Institute, Columbus, Ohio

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

3. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Hospital, Columbus, Ohio

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

4. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

   BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University James Cancer Center, Columbus, Ohio

   Locations

   21 in total

   Run by

   OncoC4, Inc.

   See if you can join NCT06635785 on ClinicalTrials.gov

5. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

6. XTX301 in Patients With Advanced Solid Tumors

   This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University Wexner Medical Center, Columbus, Ohio

   Locations

   12 in total

   Run by

   Xilio Development, Inc.

   See if you can join NCT05684965 on ClinicalTrials.gov

7. Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

   This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461,…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio

   Locations

   8 in total

   Run by

   Senhwa Biosciences, Inc.

   See if you can join NCT04890613 on ClinicalTrials.gov

8. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

   This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University, Columbus, Ohio

   Locations

   28 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT04145622 on ClinicalTrials.gov

9. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

   This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University - Comprehensive Cancer Center, Columbus, Ohio

   Locations

   14 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06241456 on ClinicalTrials.gov

10. Study of SGR-3515 In Participants With Advanced Solid Tumors.

    The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ohio State University, Columbus, Ohio

    Locations

    14 in total

    Run by

    Schrödinger, Inc.

    See if you can join NCT06463340 on ClinicalTrials.gov